Equities analysts expect Sio Gene Therapies, Inc. (NASDAQ:SIOX) to report earnings of ($0.11) per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Sio Gene Therapies’ earnings, with the highest EPS estimate coming in at ($0.02) and the lowest estimate coming in at ($0.20). Sio Gene Therapies reported earnings of ($0.54) per share during the same quarter last year, which would indicate a positive year over year growth rate of 79.6%. The business is scheduled to issue its next quarterly earnings results on Wednesday, June 9th.
According to Zacks, analysts expect that Sio Gene Therapies will report full-year earnings of ($0.73) per share for the current financial year, with EPS estimates ranging from ($0.88) to ($0.61). For the next year, analysts anticipate that the company will report earnings of ($0.81) per share, with EPS estimates ranging from ($0.84) to ($0.77). Zacks Investment Research’s EPS averages are a mean average based on a survey of research firms that follow Sio Gene Therapies.
Sio Gene Therapies (NASDAQ:SIOX) last released its quarterly earnings results on Monday, February 8th. The company reported ($0.20) EPS for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.09.
A number of brokerages have issued reports on SIOX. HC Wainwright initiated coverage on shares of Sio Gene Therapies in a research note on Friday. They set a “buy” rating and a $8.00 price target on the stock. Zacks Investment Research downgraded shares of Sio Gene Therapies from a “buy” rating to a “hold” rating in a research note on Saturday, April 3rd. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the company. Sio Gene Therapies presently has an average rating of “Buy” and an average price target of $10.92.
In other news, CEO Pavan Cheruvu acquired 100,000 shares of Sio Gene Therapies stock in a transaction dated Tuesday, March 23rd. The shares were acquired at an average cost of $2.48 per share, for a total transaction of $248,000.00. Following the acquisition, the chief executive officer now owns 180,426 shares of the company’s stock, valued at $447,456.48. The acquisition was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 4.20% of the stock is owned by company insiders.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Creative Planning purchased a new stake in Sio Gene Therapies during the fourth quarter worth approximately $129,000. GSA Capital Partners LLP purchased a new stake in shares of Sio Gene Therapies during the 4th quarter worth approximately $985,000. Primecap Management Co. CA acquired a new position in shares of Sio Gene Therapies in the 4th quarter valued at $146,000. Wells Fargo & Company MN purchased a new position in shares of Sio Gene Therapies in the 4th quarter valued at $100,000. Finally, Opaleye Management Inc. acquired a new stake in Sio Gene Therapies during the 4th quarter worth $5,560,000. Institutional investors and hedge funds own 24.12% of the company’s stock.
Shares of SIOX stock traded down $0.07 on Tuesday, hitting $2.63. The stock had a trading volume of 532,857 shares, compared to its average volume of 1,309,340. The company’s 50 day moving average price is $2.61 and its 200-day moving average price is $2.73. Sio Gene Therapies has a 1 year low of $1.86 and a 1 year high of $5.74. The firm has a market capitalization of $124.27 million and a P/E ratio of -1.33.
Sio Gene Therapies Company Profile
Sio Gene Therapies, Inc, a clinical-stage gene therapy company, focuses on developing various product candidates for debilitating neurodegenerative diseases. The company's clinical-stage programs include AXO-Lenti-PD program for the treatment of Parkinson's disease; AXO-AAV-GM1 program for the treatment of GM1 gangliosidosis; and AXO-AAV-GM2 program for the treatment of GM2 gangliosidosis.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sio Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sio Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.